FDA warns of liver injury risk from tolvaptan

01/28/2013 | Medscape (free registration)

Otsuka America Pharmaceutical's kidney drug Samsca, or tolvaptan, may cause irreversible and potentially deadly liver injury, and providers should promptly conduct liver tests on patients reporting symptoms, according to the FDA. Otsuka informed the FDA that three trial participants who took tolvaptan developed liver problems, and their conditions improved after they stopped taking the drug.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Food Lawyer
Cargill
Wayzata, MN
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ